Insulet new OmniPod should be catalyst in FY12, says Barrington After Insulet reported weaker than expected Q4 results, Barrington reduced its FY12 estimates but the firm expects the company's stock to outperform its group in 2012. The firm believes that the company's risk will decline this year and it reiterates an Outperform rating.
News For PODD From The Last 14 Days
Check below for free stories on PODD the last two weeks.